Laminin 121 E8

Produktanfrage

Laminin 121 E8 Molekülhintergrund

Laminin-121 is one of the α1 chain containing laminins. The α1 chain is detected at the 2-cell stage of the pre-implantation mouse embryo and is subsequently expressed mainly in many epithelial tissues during organogenesis. Laminin-121 showed the highest affinity to α6β1 and α7β1 integrins and furthermore, laminin-121 most effectively supported neurite outgrowth.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Atacicept	TACI-Ig	Phase 3 Clinical	Zymogenetics Inc	Glomerulonephritis, IGA; Kidney Diseases; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Urinary Bladder Diseases; Lupus Erythematosus, Systemic	Details
Povetacicept	ALPN-303; ALPN 30x	Phase 3 Clinical		Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Glomerulonephritis, IGA; Sjogren's Syndrome; Glomerulonephritis, Membranous; Lupus Nephritis; Lupus Erythematosus, Systemic; Anemia, Hemolytic, Autoimmune; Inflammation; Cytopenia; Glomerulonephritis	Details
Rozibafusp alfa	AMG-570; MEDI-0700	Phase 2 Clinical	Amgen Inc	Arthritis, Rheumatoid; Lupus Erythematosus, Systemic	Details
Tabalumab	LY-2127399	Phase 2 Clinical	Eli Lilly And Company	Multiple Sclerosis, Relapsing-Remitting; Dermatomyositis; Arthritis, Rheumatoid; Autoimmune Diseases; Scleroderma, Systemic; Multiple Myeloma; Connective Tissue Diseases; Arthritis, Juvenile; Multiple Sclerosis; Lupus Erythematosus, Systemic; Kidney Failure, Chronic; Pemphigus	Details
UBP-1213	UBP-1213	Phase 1 Clinical	Wuhan Huaxin Kangyuan Biomedicine Co Ltd, Shanghai Junshi Biosciences Co Ltd	Lupus Erythematosus, Systemic	Details
Autologous CAR-T cell therapy expressing the BAFF-ligand	LMY-920; LUMT1A22	Phase 1 Clinical	Luminary Therapeutics Inc	Sjogren's Syndrome; Scleroderma, Systemic; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Mantle-Cell	Details
UBP1213sc	UBP1213sc	Phase 1 Clinical		Lupus Nephritis; Lupus Erythematosus, Systemic	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Telitacicept	RCT-18; RC-18; RCT18; RC18	Approved	RemeGen Co Ltd		Mainland China	Lupus Erythematosus, Systemic	RemeGen Co Ltd	2021-03-09	Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Nephrosis; Immunoglobulin G4-Related Disease; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Lupus Nephritis; Neuromyelitis Optica; Lupus Erythematosus, Systemic	Details
Belimumab	BmAb; GSK-1550188; HGS-1006	Approved	Glaxosmithkline Plc	Benlysta, 倍力腾	United States	Lupus Erythematosus, Systemic	Human Genome Sciences Inc	2011-03-09	Antiphospholipid Syndrome; Leukemia, Lymphocytic, Chronic, B-Cell; Bronchial Diseases; Emphysema; Pulmonary Disease, Chronic Obstructive; Waldenstrom Macroglobulinemia; Hepatitis, Autoimmune; Lymphopenia; Rheumatic Diseases; Sjogren-Larsson Syndrome; Lupus Erythematosus, Systemic; systemic sclerosis-associated interstitial lung disease; Mixed Connective Tissue Disease; Myasthenia Gravis; Glomerulonephritis, Membranous; Lung Diseases, Interstitial; Lupus Nephritis; Graft vs Host Disease; Purpura; Arthritis, Rheumatoid; Scleroderma, Systemic; Myositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatosis with Polyangiitis; Rejection of renal transplantation	Details